Related Experiment Video

Updated: Feb 28, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.3K

Application of omics in predicting anti-TNF efficacy in rheumatoid arthritis

Xi Xie1, Fen Li2, Shu Li1

  • 1Department of Rheumatology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.

Clinical Rheumatology
|June 11, 2017
PubMed

Insights

Predicting rheumatoid arthritis (RA) treatment response to tumor necrosis factor (TNF) antagonists is crucial. Identifying biomarkers through omics data can optimize personalized therapy for RA patients unresponsive to anti-TNF drugs.

Area of Science:

  • Immunology
  • Rheumatology
  • Genomics

Background:

  • Rheumatoid arthritis (RA) is a systemic autoimmune disease causing joint erosion.
  • Tumor necrosis factor (TNF) antagonists are common biologic treatments for RA.
  • A significant portion of RA patients (one-third) do not respond adequately to TNF antagonists.

Purpose of the Study:

  • To explore the potential of omics technologies for predicting treatment response to TNF antagonists in RA.
  • To identify biomarkers that distinguish between responders and non-responders to anti-TNF therapy.
  • To enable personalized treatment strategies for RA patients.

Main Methods:

  • Comparative analysis of omics data (genomics, transcriptomics, proteomics, metabolomics) between RA patients who respond and do not respond to TNF antagonists.
  • Investigation of molecular differences associated with therapeutic outcomes.

Main Results:

  • Omics data comparisons reveal potential molecular distinctions between responders and non-responders to TNF antagonists.
  • Identification of candidate biomarkers for predicting anti-TNF therapy efficacy in RA.

Conclusions:

  • Biomarker discovery using omics approaches holds promise for predicting TNF antagonist response in RA.
  • Personalized medicine strategies can be enhanced by predicting treatment outcomes before initiating anti-TNF therapy.
  • Further research is warranted to validate these biomarkers for clinical application in RA management.
Keywords:
Anti-TNF therapyGenomicsMetabolomicsProteomicsRheumatoid arthritisTranscriptomics

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.2K
Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

9.7K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
660
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.4K
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.9K